ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care– FDA statistics indicate that more than 33 million Americans, teens and older, misused extended-release and long-acting (ER/LA) opioids during 2007, up from 29 million in 2002. In response to the growing epidemic of opiate abuse the FDA mandated, in July of 2012, new safety measures for ER/LA opioid medications. These measures emphasize education for prescribers and patients under the umbrella of a risk evaluation and mitigation strategy or REMS.
Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy as well as possible misuse.
Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques as well as appropriate discontinuation strategies.
Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics and properly use evidence-based tools while assessing for adverse effects.
Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
Review/assess general and product-specific drug information concerning ER/LA opioid analgesics and identifying potential adverse effects of ER/LA opioids.
4.0 Free AMA Pra CAT 1 CME for Physicians